This cohort descriptive study summarizes the epidemiological, clinical, and laboratory characteristics of the Rift Valley fever (RVF) epidemic that occurred in Saudi Arabia from 26 August 2000 through 22 September 2001. A total of 886 cases were reported. Of 834 reported cases for which laboratory results were available, 81.9% were laboratory confirmed, of which 51.1% were positive for only RVF immunoglobulin M, 35.7% were positive for only RVF antigen, and 13.2% were positive for both. The mean age ‫ע(‬ standard deviation) was years, and the ratio of male to female patients was 4:1. Clinical and laboratory features included 46.9 ‫ע‬ 19.4 fever (92.6% of patients), nausea (59.4%), vomiting (52.6%), abdominal pain (38.0%), diarrhea (22.1%), jaundice (18.1%), neurological manifestations (17.1%), hemorrhagic manifestations (7.1%), vision loss or scotomas (1.5%), elevated liver enzyme levels (98%), elevated lactate dehydrogenase level (60.2%), thrombocytopenia (38.4%), leukopenia (39.7%), renal impairment or failure (27.8%), elevated creatine kinase level (27.3%), and severe anemia (15.1%). The mortality rate was 13.9%. Bleeding, neurological manifestations, and jaundice were independently associated with a high mortality rate. Patients with leukopenia had significantly a lower mortality rate than did those with a normal or high leukocyte count (2.3% vs. 27.9%; odds ratio, 0.09; 95% confidence interval, 0.01-0.63).
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Rift Valley fever (RVF) is an acute zoonotic viral disease that affects ruminant animals and humans [1] . The disease is named after the Rift Valley of East Africa, where the etiologic virus was first isolated in 1930 during an investigation into an epidemic of infection among sheep on a farm in the Rift Valley in Kenya [2] . It was possible to retrospectively identify epizootic outbreaks caused by this virus as far back as 1912 [3] . Since 1930, more than 30 outbreaks of this disease have occurred in Africa [4] . Outbreaks were reported exclu-sively from sub-Saharan Africa until 1977-1978, when infections in 18,000 persons and 598 deaths were reported in Egypt [5, 6] . In 1987, after dam construction on the Senegal River caused flooding in the lower Senegal River area, a major epidemic, which caused 200 human deaths, occurred for the first time in Mauritania [7] . Another outbreak of RVF occurred in Egypt in 1993, when 41 cases of ocular disease and an estimated 600-1500 infections were reported [8] . The last major outbreak occurred in East Africa (Kenya and Somalia) in 1997-1998 [9] . Epidemics of RVF were limited to the African continent until 2000.
On 11 September 2000, the Ministry of Health (MOH) of the Kingdom of Saudi Arabia (Riyadh) received reports of unexplained severe hepatitis in 7 patients from the Jizan region at the southwestern border of Saudi Arabia. A team from the MOH started inves- tigations within 24 h after notification. Clinical manifestations included low-to-moderate-grade fever, abdominal pain, vomiting, diarrhea, and elevated liver enzyme levels progressing to liver failure, encephalopathy or encephalitis, disseminated intravascular coagulation (DIC), renal failure, and, in 5 of the 7 patients, death. An unusual disease with abortion storms and deaths among sheep in the region was also described by the villagers. On the basis of a clinical diagnosis of acute viral hemorrhagic fever in humans and the presence of a concomitant disease in domestic animals with deaths and abortions, the MOH team made a preliminary diagnosis of RVF within 48 h after notification. Serum specimens and a liver biopsy specimen obtained from a patient who died were sent to the Special Pathogens Branch of the Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia, for diagnostic testing. On 15 September 2000, laboratory tests at the CDC confirmed the diagnosis of RVF, using ELISA for RVF virus antigen and RVF IgM detection, RVF RT-PCR, RVF virus isolation, and RVF-specific immunohistochemical testing. Subsequently, the health authorities of the Republic of Yemen realized that a similar, hitherto undiagnosed, disease that was noticed among humans and sheep for several weeks in a northern region of Yemen bordering Jizan region was perhaps also caused by RVF. This was subsequently confirmed to be a simultaneous epidemic of RVF in the Republic of Yemen with the assistance of a team from the World Health Organization (WHO). The present study summarizes the epidemiological, clinical, and laboratory characteristics of this first confirmed occurrence of RVF outside Africa.
METHODS
The regions of the epidemic: Jizan, Asir, and Al-Qunfuda. The Jizan region is located in the southwest of Saudi Arabia, bordering the northwestern region of Yemen (figure 1). The region is inhabited by ∼1,025,318 people. It comprises 130 districts and the main city, Jizan, which is a seaport on the Red Sea. The climate is hot and humid most of the year. Most inhabitants work as farmers and raise domestic animals for a livelihood. Electric power is not yet available for the vast majority of the remote villages about which the epidemic centered. Air-conditioning and the use of electric fans are therefore not possible in these areas. As a result, villagers, particularly men, frequently sleep outdoors to avoid the high indoor temperatures and, thus, are intensely exposed to mosquito bites.
Within 3 weeks after the onset of the epidemic in Jizan, the disease appeared on the Tehama Plain of the adjacent region, Asir, and, to a lesser extent, in the Al-Qunfuda area in the Makkah region (figure 1). The Asir region is located northeast of Jizan. The majority of the Asir region consists of the Sarawat Mountains; the area referred to as "the Tehama Plain" is only a narrow coastal strip. The Tehama Plain is considered to be a geographic extension of the Jizan region. The population of Asir is ∼1,297,994 people, ∼29% of whom live on the Tehama Plain. Al-Qunfuda is a further northward extension of this coastal plain in the Makkah region. The population of AlQunfuda is ∼55,543 people. The social and environmental conditions in these 3 epidemic areas are similar.
Health care facilities in the epidemic regions. Health care facilities in the areas of the RVF epidemic included 13 hospitals and 128 primary health care centers (PHCCs) Data collection. Suspected cases were identified through an elaborate preexisting system of PHCCs that referred patients with suspected RVF to district hospitals for medical assessment and hospitalization. Patients presenting or referred to district hospitals with suspected RVF were reviewed at hospital admission, and data were recorded on a standard case report form. Information collected included patient demographic characteristics, risk factors for RVF virus infection, clinical manifestations, and laboratory results. Information related to mortality was obtained from the central operations room in the MOH, which received this information from the epidemic regions on a daily basis.
Specimens obtained. Blood specimens were obtained at admission to the hospital from all hospitalized patients with suspected RVF. Within 24 h after obtainment, specimens were transported in special containers on dry ice to the Central Laboratory in Riyadh, the capital of Saudi Arabia. Initially, specimens were then transported to the CDC for confirmatory testing. Subsequently, a laboratory was established for RVF diagnosis at the Central Laboratory in Riyadh with the assistance of the CDC.
Laboratory confirmation. ELISAs were used to detect RVF virus antigen and specific IgM in patient serum or blood samples using methods described elsewhere [10] , as adapted for RVF. The RVF virus antigen detection assay used polyclonal hyperimmune ascitic fluid raised against RVF virus strain Zagazig 501 as the capture antibody and rabbit hyperimmune serum raised against RVF virus Zagazig 501 as the detector antibody. RVF virus-specific IgM antibody was detected by IgM antibody-capture ELISA, with inactivated RVF virus-infected cell slurry prepared as described elsewhere [10] . The first group of cases were also confirmed by isolation and identification of the virus from serum or blood specimens, detection of viral RNA in serum or blood specimens using RT-PCR, and RVFspecific immunohistochemical testing of a liver biopsy specimen using methods described elsewhere [11] [12] [13] . Specimens were processed in a laminar flow safety cabinet and treated to inactivate the virus before serological testing (g irradiation was used in Atlanta, and detergent and heat were used in Riyadh).
Treatment. All patients with RVF received supportive care with intravenous fluids and, when indicated, ionotropic support, blood and fresh frozen plasma transfusion, mechanical ventilation, hemodialysis, and antimicrobial therapy for secondary bacterial or fungal infection. No specific antiviral medication was used for therapy.
Data processing. Epi Info, version 6.04b (CDC), was used for data entry and analysis. SPSS, release 7.5.1 (SPSS), was used for multivariate analysis. P р .05 denoted statistical significance. Apart from 2 fatal cases that fulfilled only the sixth case definition, all other reported cases fulfilled у2 of the other 5 case definitions. Table 1 shows the sensitivity, specificity, and positive and negative predictive values of the case definitions.
RESULTS

The
Of 886 reported patients, data from RVF-confirmatory laboratory studies were available for 834 patients, of whom 683 (81.9%) had laboratory-confirmed cases. Of 683 confirmed cases, 354 (51.8%) were reported from Asir, 299 (43.8%) were reported from Jizan, and 30 (4.4%) were reported from AlQunfuda. Of the 299 patients who acquired RVF infection in NOTE. For specific case definitions, see Methods. Only 2 cases (0.2%) fulfilled the sixth case definition, and both were laboratory confirmed. Therefore, it was not possible to calculate the sensitivity, specificity, PPV, and NPV for this case definition. NA, not applicable.
Jizan, 13 received diagnoses outside of this region (5 cases were diagnosed in Riyadh, 3 were diagnosed in Jeddah, 2 were diagnosed in the Eastern Region, 2 were diagnosed in Al-Ahsa, and 1 was diagnosed in Makkah). Table 2 presents the demographic characteristics of 683 patients with confirmed RVF infection. Of 886 patients with clinically suspected RVF, 3 patients were !10 years of age, but none of these patients had laboratory-confirmed RVF. The disease predominantly affected male patients, with a ratio of male to female patients of 4:1. Table 3 shows the frequency of patients reporting exposure to mosquitoes and/or animals (mainly sheep and goats), and the frequency of patients reporting animal abortion and animal death. Table 4 presents the clinical features of patients with laboratory-confirmed RVF infection. Table 5 shows the laboratory characteristics at hospital admission of patients hospitalized with laboratory-confirmed RVF. Of 457 patients with confirmed cases for whom hemoglobin concentrations were available, 69 patients (15.1%) had severe anemia (hemoglobin concentration, !80 g/L) characterized by an abrupt decrease in the hemoglobin concentration and an elevated LDH enzyme level suggesting acute hemolysis. Approximately 45.5% of the patients with severe anemia had evidence of DIC, which was defined as thrombocytopenia (platelet count, ! platelets/L) associated with prolon-9 100 ϫ 10 gation of partial thromboplastin time of 11.2 the control value. Of 450 patients with confirmed cases for whom platelet counts were available, 173 (38.4%) had thrombocytopenia, of whom 37.9% had evidence of DIC. Of 311 patients for whom CK enzyme levels were available, 85 (27.3%) had elevated CK enzyme levels. Tests for myoglobinuria and fractionation of CK, to determine the origin of CK, were not available in the hospitals in the epidemic regions. Approximately 27.3% of patients with high CK enzyme levels had CNS manifestations suggestive of encephalitis. Shock-induced muscle ischemia was unlikely to be the explanation for the increase in CK enzyme levels, because there was no difference in the frequency of shock between patients with high CK enzyme levels and those with normal CK enzyme levels (9.1% vs. 11.1%; ). None of P p 1.0 the patients with elevated CK enzyme levels had received an intramuscular injection before measurement of the CK enzyme level.
The 
DISCUSSION
This epidemic of RVF in southwestern Saudi Arabia coincided with simultaneous occurrences of this disease in Yemen. These epidemics represent the first documented evidence of RVF virus transmission outside of Africa. It is speculated that the RVF virus was introduced into the Arabian peninsula in 1997-1998 during the RVF epidemic in east Africa via introduction of infected imported livestock or via windborne infected mosquitoes, and that climatic conditions have promoted sufficient vector populations to support transmission in Saudi Arabia and Yemen. Two lines of evidence support this speculation. First, the current epidemic began spontaneously in geographically diverse areas in Saudi Arabia and Yemen, suggesting that dissemination of the virus probably occurred before the epidemic period. Second, the genetic sequence of the virus isolated in Saudi Arabia and Yemen is closely related to that of the virus isolated in the 1997-1998 outbreak in east Africa [11] . This virgin-soil epidemic in the Arabian Peninsula emphasizes the threat of the introduction of the virus into other parts of the world.
Acute hepatitis of various degrees of severity was the key manifestation of RVF in this epidemic. Renal failure was a common, previously undescribed complication of RVF occurring in one-quarter of patients. Other complications observed in this epidemic included thrombocytopenia, CNS involvement, severe anemia, hemorrhagic manifestations, and vision loss or scotomas. Nausea, vomiting, abdominal pain, and diarrhea were the most common presenting complaints. This gastroenteritis-like clinical presentation contrasts with the in- fluenza-like illness described in previous RVF epidemics in Africa [1, 4, [14] [15] [16] . The disease was notably rare in children !10 years of age, an observation that has been noted elsewhere [17] . The infection in this epidemic appears to have been primarily transmitted by mosquito bites and, to a lesser extent, by direct contact with infected animals, primarily sheep and goats. Elevated liver enzyme levels, with a ratio of AST level to ALT level of ∼1.5-2:1 was the most common laboratory abnormality. Elevated LDH and CK enzyme levels were also commonly observed. Because the facility to fractionate CK to determine its source was not available at the hospitals where patients were admitted, it could only be speculated that, in approximately one-quarter of patients with high CK enzyme levels, the source of this enzyme was the brain, because associated CNS manifestations suggested encephalitis. In the remaining three-quarters of patients with high CK enzyme levels, the source of the enzyme was unknown.
Acute hemolysis was the most likely explanation for the severe anemia observed in 15.1% of patients. Approximately onehalf of patients with severe anemia had evidence of DIC, which suggests that microangiopathic destruction was the cause of the hemolysis. In the other one-half, the most likely explanation of the hemolysis was immune-mediated destruction of RBCs. Similarly, only one-third of the patients with thrombocytopenia had evidence of DIC, which suggests consumption as a cause; in the remaining two-thirds, immune-mediated destruction was a possible explanation.
In this epidemic, both antigen and IgM detection assays were used to confirm the diagnosis of RVF. Approximately one-third of confirmed cases were only antigen positive, and one-half were only IgM positive; one-eighth were both antigen positive and IgM positive. Therefore, it is essential to use a combination of tests that can detect the virus during the acute stage of the disease (antigen, RT-PCR, and/or viral culture) and during the convalescent period (serological tests for RVF IgM). The reported case-fatality rate for RVF is generally 1%-3%, but it can be as high as 50% among patients with hemorrhagic manifestations or other complications [18] . The relatively high case-fatality rate in our patients (13.9%) likely reflects the fact that it represented mortality for patients with more-severe infections. True mortality rates can only be derived from population-based seroprevalence studies to determine the true incidence of RVF. The progressively increasing rate of mortality associated with aging in patients aged у60 years may be due to the declining immunity associated with aging. Patients aged 10-39 years also had increased mortality, compared with other age groups. This was perhaps related to more-intense exposure to infected mosquitoes or animals, because patients in this age group were more likely to be involved in farming, fieldwork, and care of animals. The high mortality rate among patients from Yemen is likely associated with late presentation. Most of the Yemeni patients were not legal residents of Saudi Arabia, and, as a result, many of them sought medical advice very late in the course of their illness. In addition, many of them had no shelter and thus had to sleep outdoors, exposing themselves to intense mosquito bites and, thus, higher infective doses of the virus. The observation that most Yemeni patients who died were 10-39 years of age was another factor that contributed to the increased mortality in this age group. Interestingly, patients with leukopenia had a significantly lower mortality rate, compared with those who had leukocyte counts of у leu- 9 3 ϫ 10 kocytes/L. To our knowledge, this observation has not been reported with RVF or any other infection.
Many aspects of RVF disease remain to be elucidated. Whether the RVF virus will establish endemicity in the Arabian peninsula, causing low-grade transmission, or recur episodically with transmission-free intervals between the episodes remains to be determined. The pathogenesis of the liver, renal, CNS, retinal, and hematological complications is still unknown. Elucidation of these aspects of the disease may have an important implication on the development of therapeutic interventions to treat the disease or prevent its complications.
In conclusion, this epidemic of RVF in southwestern Saudi Arabia and the neighboring northwestern regions of Yemen represented the first occurrence of this disease outside of Africa and emphasized the potential for the spread of this disease to other parts of the world. Unlike previously described epidemics, detailed clinical and laboratory description of RVF was possible because of the presence of well-structured and developed health care system and facilities in Saudi Arabia. 
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